drugset / Trial / NCT01058096

Safety and Efficacy of Cariprazine for Mania

NCT01058096

Phase 3 Completed 323 enrolled Forest Laboratories Gedeon Richter Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar I disorder.

Timeline

Start
2010-02
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 3 mg Oral
Subject Cariprazine Small molecule 12 mg Oral